Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: A new personalized promising concept

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 7, 2013, Pages 1057-1068

  Garin, E ^a,b,c   Lenoir, L ^a,b,c   Edeline, J ^b,d   Laffont, S ^a   Mesbah, H ^d   Poree P ^d   Sulpice, L ^c,e   Boudjema, K ^b,c,e   Mesbah, M ^f   Guillygomarc'H, A ^e   Quehen, E ^e   Pracht, M ^d   Raoul, J L ^g   Clement, B ^c   Rolland, Y ^d   Boucher, E ^c,d  

^a CS 44229   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c INSERM   (France)

^d Eugène Marquis Hospital   (France)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g INSTITUT PAOLI CALMETTES   (France)

Author keywords

Dosimetry; Liver; Microspheres; Radioembolization; Radionuclide therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; BILIRUBIN; IODINATED POPPYSEED OIL; MACROSALB TC 99M; MICROSPHERE; MICROSPHERE Y 90; SORAFENIB; THERASPHERE; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BOOSTED SELECTIVE INTERNAL RADIATION THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DOSIMETRY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PORTAL VEIN THROMBOSIS; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL RATE; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; FEMALE; GLASS; HUMANS; INDIVIDUALIZED MEDICINE; LIVER; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; RADIOMETRY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; SAFETY; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84879507747     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2395-x     Document Type: Article

References (31)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-50.
2. Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med. 1994;35:1782-7.
3. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52-64.
4. Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741-9.
5. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium(90) radioembolization for intermediate-advanced hepatocarcinoma: A phase II study. Hepatology. 2012. doi: 10.1002/hep.26014.
6. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al.; European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868-78.
7. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9(8):1920-8.
8. Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141(2):526-35, 535.e1-2.
9. Jelic S, Sotiropoulos GC; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(5):v59-64.
10. Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012;56(2):464-73.
11. Lau WY, Lai EC, Leung TW. Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review. Int J Radiat Oncol Biol Phys. 2011;81(2):460-7.
12. Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, et al.; Technology Assessment Committee; Interventional Oncology Task Force of the Society of Interventional Radiology. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22(3):265-78.
13. Chiesa C, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with 90Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging. 2011;55(2):168-97.
14. Garin E, Lenoir L, Rolland Y, Edeline J, Mesba H, Laffont S, et al. 99mTc-MAA SPECT/CT based dosimetry accurately predicts tumour response and survival in HCC patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53(2):255-63.
15. Garin E, Rolland Y, Lenoir L, Pracht M, Mesbah H, Porée P, et al. Utility of quantitative Tc-MAA SPECT/CT for yttrium-labelled microsphere treatment planning: calculating vascularized hepatic volume and dosimetric approach. Int J Mol Imaging. 2011;2011:398051.
16. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115(3):616-23.
17. Sato KT, Omary RA, Takehana C, Ibrahim S, Lewandowski RJ, Ryu RK, et al. The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol. 2009;20(12):1564-9.
18. Cremonesi M, Ferrari M, Bartolomei M, Orsi F, Bonomo G, Aricò D, et al. Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. Eur J Nucl Med Mol Imaging. 2008;35(11):2088-96.
19. Becker S, Laffont S, Rolland Y, Lecloirec J, Boucher E, Raoul JL, et al. Dosimetric evaluation and therapeutic response to vectorized internal radiation therapy of hepatocarcinomas using iodine-131 labelled lipiodol. Nucl Med Commun. 2008;29(9):815-25.
20. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology. 2009;49(4):1185-93.
21. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821-9.
22. Garin E, Rolland Y, Boucher E. Pre-therapeutic dosimetric evaluation and selective internal radiation therapy of hepatocellular carcinoma using yttrium-90-loaded microspheres. J Hepatol. 2013. doi: 10.1016/j.jhep.2012.11. 050.
23. Ho S, Lau WY, Leung TWT, Chan M, Johnson PJ, Li AKC. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293-8.
24. Knesaurek K, Machac J, Muzinic M, DaCosta M, Zhang Z, Heiba S. Quantitative comparison of yttrium-90 (90Y)-microspheres and technetium-99m (99mTc)-macroaggregated albumin SPECT images for planning 90Y therapy of liver cancer. Technol Cancer Res Treat. 2010;9(3):253-62.
25. Knesaurek K, Machac J, Heiba S, Cacinovic C, Zhang Z. Can correlation between Y-90 and Tc-99m MAA SPECT/CT image predict clinical outcome in hepatic Y-90 microsphere therapy. Eur J Nucl Med Mol Imaging. 2010;37(2):S293. Abstract.
26. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16(2 Pt 1):195-203.
27. Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74(5):1494-500.
28. Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med. 2010;51(9):1377-85.
29. Awada A, Vandone AM, Aftimos P. Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology. Curr Opin Oncol. 2012;24(3):297-304.
30. Hodgson DR, Wellings R, Harbron C. Practical perspectives of personalized healthcare in oncology. N Biotechnol. 2012;29(6):656-64.
31. Dieudonné A, Garin E, Laffont S, Rolland Y, Lebtahi R, Leguludec D, et al. Clinical feasibility of fast 3-dimensionnal dosimetry of the liver for treatment planning of hepatocellular carcinoma with 90Y-microspheres. J Nucl Med. 2011;52(12):1930-7.